Sanofi Multiple Sclerosis Drug Delays Disability Progression in Trial
A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in other clinical studies. Continue reading View comments